Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 8/20 | 0.49 |
| ▸ | CDK2 | P24941 | 6/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.38 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.37 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12522769 | 0.82 | CDK1 (0.53) | CDK1CDK2CCNB1CCNE1ADORA2A | |
| SCHEMBL15887583 | 0.82 | CDK1 (0.47) | CDK1CDK2CCNB1CCNE1CCNA2 | |
| SCHEMBL22058129 | 0.81 | CDK1 (0.55) | CDK1CDK2CCNB1CCNE1CCNA2 | |
| SCHEMBL12522765 | 0.79 | CDK1 (0.50) | CDK1CDK2CCNB1CCNE1ADORA2A | |
| SCHEMBL16259446 | 0.79 | CDK1 (0.44) | CDK1CDK2CCNB1CCNE1CCNA2 | |
| SCHEMBL20857246 | 0.78 | CDK1 (0.49) | CDK1CDK2CCNB1CCNE1ADORA2A | |
| SCHEMBL22915720 | 0.77 | CDK1 (0.48) | CDK1CDK2CCNB1CCNE1ADORA2A | |
| SCHEMBL5929983 | 0.76 | CCNE1 (0.43) | CDK1CDK2CCNB1CCNE1HSP90AA1 | |
| SCHEMBL14087936 | 0.76 | CDK1 (0.47) | CDK1CDK2CCNB1CCNE1CCNA2 | |
| SCHEMBL24021902 | 0.76 | CDK1 (0.53) | CDK1CDK2CCNB1CCNE1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190345192-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345192-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | TP53, MYC, CDC73 | CDK1 236/4885CDK2 304/4885CCNB1 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.